​

Our unique assays enable the real-time monitoring of protein biomarkers and drug targets.  Many oncology therapeutics function by altering the post-translational modifications occurring to the actual drug target or downstream proteins within the targeted pathway.  Understanding what is happening at the protein level, including their activation status and post-translational modifications such as phosphorylation, acetylation, and glycosylation, is critical for understanding a drug's MOA, diagnosing and monitoring disease progression, establishing individual prognosis, confirming genomic predictions, and tracking treatment responses.

​

​

​

MDI works side-by-side with pharmaceutical companies, helping them do faster and more confident drug discovery and clinical development.